What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2025-11-03 compared with 2025-08-13 · 158 added, 222 removed, 39 unchanged (91% of the section changed)

OTHER INFORMATION.

June 30, 2025 , none of our officers or directors, as defined in Rule 16a-1(f), informed us of the adoption , modification or termination

of any “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined

in Item 408 of Regulation S-K.

(c) During the nine months ended September 30, 2025, none of our officers or directors, as defined in Rule 16a-1(f), informed us of the adoption , modification or termination of any “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.

The following exhibits are filed herewith:

Exchange Agreement, dated February 8, 2016 (1)

of Incorporation of the Company (2)

of the Company, as amended (44)

of Amendment to Articles of Incorporation filed on March 21, 2016 (4)

of Amendment to Articles of Incorporation filed on December 21, 2016 (5)

of Amendment to Articles of Incorporation filed on March 30, 2020 (6)

of Amendment to Articles of Incorporation filed on February 17, 2021 (29)

of Amendment to Articles of Incorporation filed on July 24, 2023 (45)

to Bylaws (46)

of Warrant (7)

of Investor Warrant dated May 16, 2022 (32)

of Voting Rights Proxy Agreement (58)

Collaboration

Agreement dated December 29, 2015 (8)

Collaborative

Agreement and Milestone Payment Agreement dated June 9, 2016 (9)

Agreement with Kira Huang (10)

to the Collaboration Agreement dated January 12, 2017 (11)

Collaboration

Agreement with BioFirst dated July 24, 2017 (12)

Co-Development

Agreement with Rgene dated May 26, 2017 (13)

Letter Agreement dated May 22, 2024 (52)

Form of Warrant dated May 22, 2024 (52)

Loan Agreement entered by and between Cathay Bank and American BriVision (Holding) Corporation (16)

Note entered by American BriVision (Holding) Corporation (17)

of Commercial Security Agreement (18)

of Exchange Agreement entered into by and between the Company and non-US person (19)

of Exchange Agreement entered into by and between the Company and US person (20)

of Securities Purchase Agreement entered into by and between the Company and U.S.

Share Exchange Agreement, dated February 8, 2016 (1)

Articles of Incorporation of the Company (2)

Bylaws of the Company, as amended (44)

Certificate of Amendment to Articles of Incorporation filed on March 21, 2016 (4)

Certificate of Amendment to Articles of Incorporation filed on December 21, 2016 (5)

Certificate of Amendment to Articles of Incorporation filed on March 30, 2020 (6)

Certificate of Amendment to Articles of Incorporation filed on February 17, 2021 (29)

Certificate of Amendment to Articles of Incorporation filed on July 24, 2023 (45)

Amendment to Bylaws (46)

Form of Warrant (7)

Form of Investor Warrant dated May 16, 2022 (32)

Form of Voting Rights Proxy Agreement (58)

Collaboration Agreement dated December 29, 2015 (8)

Collaborative Agreement and Milestone Payment Agreement dated June 9, 2016 (9)

Employment Agreement with Kira Huang (10)

Addendum to the Collaboration Agreement dated January 12, 2017 (11)

Collaboration Agreement with BioFirst dated July 24, 2017 (12)

Co-Development Agreement with Rgene dated May 26, 2017 (13)

Lind Letter Agreement dated May 22, 2024 (52)

Lind Form of Warrant dated May 22, 2024 (52)

Business Loan Agreement entered by and between Cathay Bank and American BriVision (Holding) Corporation (16)

Promissory Note entered by American BriVision (Holding) Corporation (17)

Form of Commercial Security Agreement (18)

Form of Exchange Agreement entered into by and between the Company and non-US person (19)

Form of Exchange Agreement entered into by and between the Company and US person (20)

Form of Securities Purchase Agreement entered into by and between the Company and U.S.

investors (21)

of Securities Purchase Agreement entered into by and between the Company and non-U.S.

Form of Securities Purchase Agreement entered into by and between the Company and non-U.S.

investors (22)

and Restated American BriVision (Holding) Corporation 2016 Equity Incentive (26)

of Securities Purchase Agreement (27)

of Convertible Promissory Note (27)

Amended and Restated American BriVision (Holding) Corporation 2016 Equity Incentive (26)

Form of Securities Purchase Agreement (27)

Form of Convertible Promissory Note (27)

Amendment No.

1 to Promissory Note (28)

Venture Agreement between the Company, Lucidiam Co., Ltd.

Joint Venture Agreement between the Company, Lucidiam Co., Ltd.

And BioLite Japan K.K.

to the Collaboration Agreement dated December 29, 2015 (34)

Development Service Agreement with Rgene (portions of the exhibit have been omitted because they (i) are not material and (ii) is

the type of information that the registrant treats as private or confidential.)(31)

Note issued to Regene, dated June 16, 2022 (31)

of Securities Purchase Agreement dated May 12, 2022 (32)

Purchase Agreement(33)

of Warrant(33)

Agreement(33)

Security Agreement(33)

Security Agreement with Rgene Corporation(33)

Security Agreement with BioFirst Corporation(33)

Security Agreement(33)

Amendment to the Collaboration Agreement dated December 29, 2015 (34)

Clinical Development Service Agreement with Rgene (portions of the exhibit have been omitted because they (i) are not material and (ii) is the type of information that the registrant treats as private or confidential.)(31)

Promissory Note issued to Regene, dated June 16, 2022 (31)

Form of Securities Purchase Agreement dated May 12, 2022 (32)

Securities Purchase Agreement(33)

Form of Note(33)

Form of Warrant(33)

Security Agreement(33)

Pledge Agreement(33)

Cooperation Agreement between the Company and Zhong Hui Lian He Ji Tuan, Ltd.

Guarantor Security Agreement(33)

Trademark Security Agreement with Rgene Corporation(33)

Trademark Security Agreement with BioFirst Corporation(33)

Patent Security Agreement(33)

Stock Pledge Agreement(33)

The Cooperation Agreement between the Company and Zhong Hui Lian He Ji Tuan, Ltd.

dated August 14, 2023 (35)

to the Cooperation Agreement (36)

Agreement (37)

Agreement between the Company and AiBtl BioPharma, Inc (47)

Agreement between the BioLite and AiBtl BioPharma, Inc (47)

License Agreement between the Company and OncoX BioPharma, Inc.

Amendment to the Cooperation Agreement (36)

Letter Agreement (37)

License Agreement between the Company and AiBtl BioPharma, Inc (47)

License Agreement between the BioLite and AiBtl BioPharma, Inc (47)

Definitive License Agreement between the Company and OncoX BioPharma, Inc.

May 8, 2024 (51)

License Agreement between Rgene and OncoX BioPharma, Inc.

Definitive License Agreement between Rgene and OncoX BioPharma, Inc.

dated May 8, 2024 (51)

of 2nd Lind Note (38)

of 2nd Lind Warrant (38)

Purchase Agreement dated November 17, 2023 (38)

Amendment To Security Agreement (38)

Amendment To Guarantor Security Agreement (38)

Amendment to Guaranty (38)

Purchase Agreement dated January 17, 2024 (39)

of 3rd Placement Agent Warrant (40)

Amendment To Security Agreement (39)

Amendment To Guarantor Security Agreement (39)

Amendment to Guaranty (39)

of 3rd Lind Note (39)

of 3rd Lind Warrant (39)

Form of 2nd Lind Note (38)

Form of 2nd Lind Warrant (38)

Securities Purchase Agreement dated November 17, 2023 (38)

First Amendment To Security Agreement (38)

First Amendment To Guarantor Security Agreement (38)

First Amendment to Guaranty (38)

Securities Purchase Agreement dated January 17, 2024 (39)

Form of 3rd Placement Agent Warrant (40)

Second Amendment To Security Agreement (39)

Second Amendment To Guarantor Security Agreement (39)

Second Amendment to Guaranty (39)

Form of 3rd Lind Note (39)

Form of 3rd Lind Warrant (39)

Amendment No.

1 to 2nd Lind Note (41)

Amendment No.

2 to 2nd Lind Note (42)

Amendment No.

1 to 3rd Lind Note (43)

License Agreement between the Company and OncoX BioPharma, Inc.

License Agreement between Rgene and OncoX BioPharma, Inc.

License Agreement between the Company and ForSeeCon Eye Corporation (49)

License Agreement between BioFirst Corporationand ForSeeCon Eye Corporation (49)

of Amendment (50)

License Agreement between the Company and OncoX BioPharma, Inc.

Definitive License Agreement between the Company and OncoX BioPharma, Inc.

Definitive License Agreement between Rgene and OncoX BioPharma, Inc.

Definitive License Agreement between the Company and ForSeeCon Eye Corporation (49)

Definitive License Agreement between BioFirst Corporationand ForSeeCon Eye Corporation (49)

Form of Amendment (50)

Definitive License Agreement between the Company and OncoX BioPharma, Inc.

May 23, 2024 (53)

License Agreement between Biolite, Inc.

Definitive License Agreement between Biolite, Inc.

and OncoX BioPharma, Inc.

dated May 23, 2024 (53)

to the Definitive License Agreement between the Company and ForSeeCon Eye Corporation (54)

to the Definitive License Agreement between BioFirst Corporation and ForSeeCon Eye Corporation (54)

to the License Agreement between the Company and AiBtl BioPharma Inc.

to the License Agreement between BioLite, Inc.

Amendment to the Definitive License Agreement between the Company and ForSeeCon Eye Corporation (54)

Amendment to the Definitive License Agreement between BioFirst Corporation and ForSeeCon Eye Corporation (54)

Amendment to the License Agreement between the Company and AiBtl BioPharma Inc.

Amendment to the License Agreement between BioLite, Inc.

and AiBtl BioPharma Inc.

Agreement dated January 5, 2025 (56)

Transfer Plan dated March 31, 2025 (57)

Holding Agreement dated April 1, 2024 (57)

Lease Agreement dated April 1, 2024 (57)

to Definitive Licensing Agreement between ABVC and AiBtl dated March 11, 2025 (57)

to Definitive Licensing Agreement between BioLite and AiBtl dated March 11, 2025 (57)

Land Holding Agreement dated October 28, 2024 (57)

of Purchase Agreement (58)

Letter Agreement dated January 5, 2025 (56)

Land Transfer Plan dated March 31, 2025 (57)

Nominee Holding Agreement dated April 1, 2024 (57)

Land Lease Agreement dated April 1, 2024 (57)

Addendum to Definitive Licensing Agreement between ABVC and AiBtl dated March 11, 2025 (57)

Addendum to Definitive Licensing Agreement between BioLite and AiBtl dated March 11, 2025 (57)

Yun Zhi Yi Land Holding Agreement dated October 28, 2024 (57)

Form of Purchase Agreement (58)

Form of Voting Rights Proxy Agreement (58)

Second Amended and Restated 2016 Equity Incentive Plan (59)

Certifications

pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302

of the Sarbanes-Oxley Act of 2002.+

Certifications

pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302

of the Sarbanes-Oxley Act of 2002.+

Certifications

pursuant to 18 U.S.C.

Form of Warrant (60)

Definitive Agreement between the Company and Shuling Jiang (60)

Consulting Agreement (60)

Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+

Certifications pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*+

Certifications

pursuant to 18 U.S.C.

Certifications pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*+

5 unchanged sentences

Inline XBRL Taxonomy Extension Presentation Linkbase Document.+

Cover Page Interactive Data File (formatted as Inline XBRL and contained

in Exhibit 101).

* In accordance with SEC Release

33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

Filed herewith

(1) Incorporated by reference to

Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on February 16, 2016.

Incorporated by reference to Exhibit 3.01 to the Company’s Form

SB-2 filed on June 28, 2002

Incorporated by reference to Exhibit 3.02 to the Company’s Form

SB-2, filed on June 28, 2002

Incorporated by reference to Exhibit 4.1 to the Company’s Current

Report on Form 8-K, filed on March 28, 2016.

Incorporated by reference to Exhibit 3.4 to the Company’s Form

S-1, filed on September 13, 2016.

Incorporated by reference to Exhibit 3.1 to the Company’s Form

8-K, filed on April 7, 2020

Incorporated by reference to Exhibit 4.1 the Company’s Current

Report on Form 8-K, filed on April 24, 2020

Incorporated by reference to Exhibit 10.2 the Company’s Current

Report on Form 8-K, filed on February 16, 2016.

Incorporated by reference to Exhibit 99.1 to the Company’s Current

Report on Form 8-K, filed on June 9, 2016.

Incorporated by reference to Exhibit 10.3 to the Company’s Annual

Report on Form 10-K, filed on January 12, 2017.

Incorporated by reference to Exhibit 99.1 to the Company’s Current

Report on Form 8-K, filed on February 22, 2017.

Incorporated by reference to Exhibit 10.1 to the Company’s Current

Report on Form 8-K, filed on July 24, 2017.

Incorporated by reference to Exhibit 99.1 to the Company’s Current

Report on Form 8-K, filed on May 30, 2017.

(14) Reserved.

Incorporated by reference to Exhibit 10.3 to the Company’s Current

Report on Form 8-K, filed on September 20, 2017.

Incorporated by reference to Exhibit 10.1 to the Company’s Current

Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference to Exhibit 10.2 to the Company’s Current

Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference to Exhibit 10.3 to the Company’s Current

Report on Form 8-K, filed on February 1, 2019.

Incorporated by reference to Exhibit 10.1 to the Company’s Current

Report on Form 8-K, filed on April 24, 2020.

Incorporated by reference to Exhibit 10.1 to the Company’s Current

Report on Form 8-K, filed April 14, 2020.

Incorporated by reference to Exhibit 10.15 to the Company’s Annual

Report on Form 10-K, filed May 15, 2020.

Incorporated by reference to Exhibit 10.16 to the Company’s Annual

Report on Form 10-K, filed May 15, 2020

Incorporated by reference to Exhibit 14.1 to the Company’s Amendment

No.1 to Form S-1, filed on November 14, 2016.

Incorporated by reference to 21.1 to the Company’s Form S-1,

filed on September 13, 2016.

Incorporated by reference to Exhibit 10.9 to the Company’s Annual

Report on Form 10-K, filed May 15, 2020.

Incorporated by reference to Exhibit 10.17 to the Company’s Annual

Report on Form 10-K, filed March 16, 2021.

Incorporated by reference to the Current Report on Form 8-K filed on

November 5, 2020.

Incorporated by reference to the Current Report on Form 8-K filed on

June 8, 2021.

Incorporated by reference to the Quarterly Report on Form 10-Q filed

on May 10, 2021.

Incorporated by reference to the Current Report on Form 8-K filed on

October 8, 2021.

Incorporated by reference to the Current Report on Form 8-K filed on

June 21, 2022.

Incorporated by reference to the Current Report on Form 8-K filed on

May 12, 2022.